NRAS and non-small cell lung carcinoma: Two confirmed partial responses out of ten NRAS-mutant melanoma patients have been observed following belvarafenib treatment.432 Two patients (one endometrial cancer and one NSCLC) out of 66 with KRAS mutations had confirmed responses to lifirafenib treatment.438 Future large-scale clinical trials are warranted to validate their clinical efficacy.